Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Conditions

Breast Neoplasms 1388Neoplasms 1168Colorectal Neoplasms 626Lung Neoplasms 562Prostatic Neoplasms 538Carcinoma, Non-Small-Cell Lung 444Carcinoma, Hepatocellular 296Stomach Neoplasms 272Pancreatic Neoplasms 270Colonic Neoplasms 264Ovarian Neoplasms 231Head and Neck Neoplasms 228Rectal Neoplasms 221Melanoma 216Multiple Myeloma 204Uterine Cervical Neoplasms 198Lymphoma 195Leukemia 193Precursor Cell Lymphoblastic Leukemia-Lymphoma 191Neoplasm Metastasis 178Carcinoma, Renal Cell 177Brain Neoplasms 174Esophageal Neoplasms 173Leukemia, Myeloid, Acute 158Urinary Bladder Neoplasms 138Recurrence 123Polycystic Ovary Syndrome 122Liver Neoplasms 119Hematologic Neoplasms 117Endometrial Neoplasms 107

Interventions

Piperacillin, Tazobactam Drug Combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Observational × Gram-Positive Bacterial Infections × Clear all
NCT00167999 2007-03-15

Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

Wyeth is now a wholly owned subsidiary of Pfizer

Completed
200 enrolled

Bacterial Infections, Escherichia coli Infections, Klebsiella Infections, Gram-Positive Bacterial Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡